Free Trial

Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health

Eli Lilly and Company CEO David Ricks stands as President Donald Trump speaks about investing in America in the Cross Hall of the White House, Wednesday, April 30, 2025, in Washington. (AP Photo/Alex Brandon)

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

This could complicate access to a drug that many patients cannot afford to pay for on their own.

The formulary is maintained by CVS Health’s pharmacy benefits management business, which runs prescription drug coverage for millions of people. Employers and insurers — who pay most of the prescription bill — use the formulary to decide which drugs get coverage.

They can customize their coverage plans to include Zepbound. But CVS Health spokesman David Whitrap said most employers wind up using the standard formulary because of the discounts negotiated for them.

Patients taking Zepbound will be able to switch to Wegovy if the Lilly drug is excluded from their coverage, Whitrap said.

CVS Health also said Thursday that it will start selling Wegovy at a discounted price of about $500 monthly at thousands of drugstores for people without coverage. Novo had announced its new lower price last month.

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity due to the amount of weight people lose while taking the injections. Coverage of these drugs has been patchy due to in part to their cost and the wide swath of patients who could take them.

Shortages of the drugs also have made access challenging, but those have eased recently. That allows pharmacy benefit managers to pit the products against each other to negotiate lower prices in exchange for inclusion on a formulary.

Lilly may have to make some price cuts to restore formulary access, said Daniel Barasa, who follows the company for Gabelli Funds. But he said he thinks big employers will still include both treatments on their lists of covered drugs, leaving the choice on what to use up to patients and doctors.

Lilly said late last year that a head-to-head study of the two drugs showed that Zepbound helped patients drop more pounds.

Zepbound has emerged as one of Lilly's top sellers. Its sales jumped to $2.3 billion in the recently completed first quarter. That’s up from $517 million a year ago, during the drug’s first full quarter on the market.

Lilly shares shed more than $90 in value, falling nearly 11% to $804.06 Thursday afternoon. Broader indexes, meanwhile, rose slightly.

Should You Invest $1,000 in CVS Health Right Now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines